Stock Update: Johnson & Johnson (NYSE:JNJ) – Johnson & Johnson’s (JNJ) CEO Alex Gorsky on Q2 2014 Results – Earnings Call Transcript

Johnson & Johnson (NYSE:JNJ) [Seeking Alpha] – Good morning, and welcome to the Johnson & Johnson Second Quarter 2014 Earnings Conference Call. I would now like to turn the conference call over to Johnson & Johnson.
Read more on this.

Johnson & Johnson (JNJ), currently valued at $292.22B, opened this morning at $105.23.
 
Looking at the stock, its one day range is $102.77 to $105.47 and has traded between $85.50 and $106.74 over the past 12 months.
 
JNJ shares are currently priced at 17.86x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s -5.80x earnings multiple.
 
And for income investors, the company pays shareholders $2.80 per share annually in dividends, yielding 2.70%.
 
Consensus earnings for the current quarter by the 16 sell-side analysts covering the stock is an estimate of $1.55 per share, which would be $0.07 better than the year-ago quarter and a $0.02 sequential increase. The full-year EPS estimate is $5.90 which would be a $0.38 better than last year’s full-year earnings.
 
The quarterly earnings estimate is predicated on a consensus revenue forecast of $18.98 Billion. If reported, that would be a 6.15% increase over the year-ago quarter.
 
More recently, Barclays downgraded JNJ from Overweight to Equal Weight (Jan 10, 2014). Previously, RBC Capital Mkts upgraded JNJ from Sector Perform to Outperform.
 
With the above information in mind, readers should note that the average price target is $106.43, which is 1.14% above where the stock opened this morning.
 
Summary (NYSE:JNJ) :  Johnson & Johnson, together with its subsidiaries, is engaged in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. The Consumer segment offers a range of products used in the baby care, skin care, oral care, wound care, and women’s health fields, as well as nutritionals, over-the-counter pharmaceutical products, and wellness and prevention platforms under the JOHNSON’S, AVEENO, CLEAN & CLEAR, DABAO, JOHNSON’S Adult, LUBRIDERM, NEUTROGENA, RoC, VENDÔME, LISTERINE, BAND-AID, NEOSPORIN, STAYFREE, CAREFREE, o.b. tampon, SPLENDA, TYLENOL, SUDAFED, ZYRTEC, MOTRIN IB, and PEPCID brand names. This segment markets its products to the general public, as well as to retail outlets and distributors. The Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, cardiovascular, contraceptive, gastrointestinal, hematology, immunology, infectious diseases, metabolic, neurology, oncology, pain management, thrombosis, and vaccines. This segment distributes its products directly to retailers, wholesalers, and health care professionals for prescription use. The Medical Devices and Diagnostics segment offers various products to treat cardiovascular disease; orthopaedic and neurological products; general surgery, biosurgical, and energy products; professional diagnostic products; infection prevention products; and disposable contact lenses. This segment distributes its products to wholesalers, hospitals, and retailers, used principally in the professional fields by physicians, nurses, hospitals, and clinics. Johnson & Johnson was founded in 1885 and is based in New Brunswick, New Jersey.
 
Tag Helper ~ Stock Code: JNJ | Common Company name: Johnson & Johnson | Full Company name: Johnson & Johnson (NYSE:JNJ) .

More on this topic (What's this?) Read more on JOHNSON & JOHNSON at Wikinvest

Sharing the News


facebooktwittergoogle_plusredditlinkedinmail

Follow us for the Latest news


facebooktwittergoogle_pluslinkedinrss

NYSE, NASDAQ, Market Data, Earnings Estimates, Analyst Ratings and Key Statistics provided via Yahoo Finance, unless otherwise specified. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Jutia Group will not be liable for any errors, incompleteness or delays, or for any actions taken in reliance on the data displayed herein.

Related Articles


Comments are closed.